sorafenib has been researched along with Neoplasms, Pleural in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R | 1 |
| Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R | 1 |
| Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA | 1 |
| Aglietta, M; Basiricò, M; Canta, M; Capozzi, F; Cemmi, F; Dell'Aglio, C; Gammaitoni, L; Grignani, G; Inghilleri, S; Luisetti, M; Marchiò, S; Morbini, P; Pignochino, Y; Piloni, D; Pozzi, E; Sangiolo, D; Soster, M; Stella, GM; Zorzetto, M | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Chao, G; Dicker, DT; El-Deiry, WS; Ferrara, T; Katz, SI; Smith, CD; Wang, W; Zhou, L | 1 |
| Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM | 1 |
| Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C | 1 |
1 review(s) available for sorafenib and Neoplasms, Pleural
| Article | Year |
|---|---|
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult | 2015 |
2 trial(s) available for sorafenib and Neoplasms, Pleural
| Article | Year |
|---|---|
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
7 other study(ies) available for sorafenib and Neoplasms, Pleural
| Article | Year |
|---|---|
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred NOD; Mice, SCID; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Sorafenib; Time Factors | 2017 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib | 2020 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytoskeletal Proteins; Drug Synergism; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lung Neoplasms; Mesothelioma; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult | 2010 |